Compare GSK plc (GSK) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Sony Group Corp — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Sony Group Corp trades at $24.12 (market cap $136.87B). The key difference: Sony Group Corp is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Sony Group Corp for 96 Days on average.
| GSK | SONY | |
|---|---|---|
Market Cap | $91.88B | $136.87B |
Volume | 7,730,529 | 5,364,503 |
Sector | Health | Technology |
52-Week High | $61.18 | $30.26 |
52-Week Low | $43.24 | $19.32 |
Typical Hold Time | 93 Days | 96 Days |
Enterprise Value | $111.88B | $134.77B |
Dividend Yield | 3.9% | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Sony trades at $23.95, up 1.83% with bullish technical signals from moving averages. The company shows strong operating cash flow of $2.32 trillion for 2025 and beat earnings expectations in two of the last three quarters. Analyst consensus is strongly positive with 11 buy ratings and no sell recommendations. Recent news highlights Sony's content moat and strategic positioning in entertainment and technology sectors.
The outlook remains constructive given strong analyst support and improving cash flow trends, though investors should monitor the projected net income decline to -$221.6 billion for 2026. Key opportunities include Sony's entertainment ecosystem and AI-related growth, while risks include competitive pressures and execution challenges in maintaining profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
